Device
WATCHMAN
WATCHMAN is a medical device with 5 clinical trials. Historical success rate of 75.0%.
Total Trials
5
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph not_applicable
3
60%
Ph phase_4
1
20%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
3(75.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
60.0%
3 of 5 finished
Non-Completion Rate
40.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(2)
Detailed Status
Completed3
Withdrawn1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 4
Trials by Phase
Phase 41 (25.0%)
N/A3 (75.0%)
Trials by Status
withdrawn120%
terminated120%
completed360%
Recent Activity
0 active trials
Showing 5 of 5
completednot_applicable
WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
NCT03173534
terminatednot_applicable
Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
NCT02678871
completed
Safety and Efficacy of Left Atrial Appendage Occlusion Devices
NCT01695564
withdrawnphase_4
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
NCT02885545
completednot_applicable
ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology
NCT00851578
Clinical Trials (5)
Showing 5 of 5 trials
NCT03173534Not Applicable
WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
NCT02678871Not Applicable
Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
NCT01695564
Safety and Efficacy of Left Atrial Appendage Occlusion Devices
NCT02885545Phase 4
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
NCT00851578Not Applicable
ASA Plavix Feasibility Study With WATCHMAN Left Atrial Appendage Closure Technology
All 5 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 5